AstraZeneca outlook seen safer after 2030 amid pipeline newsflow
J.P. Morgan said AstraZeneca is due to report results from late-stage clinical trials next year that could improve investors’ confidence in its growth beyond 2030.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.